Urinary tract infections (UTIs) caused by Escherichia coli have been historically managed with oral 31 antibiotics including the cephalosporins, fluoroquinolones and trimethoprim-sulfamethoxazole. The use 32 of these agents is being compromised by the increase in extended spectrum β-lactamase (ESBL)-33 producing organisms, mostly caused by the emergence and clonal expansion of E. coli multilocus 34 sequence typing (ST) 131. In addition, ESBL isolates show co-resistance to many of oral agents. 35
Materials and Methods 119
Bacterial isolates 120 A total of 1831 isolates of E. coli were collected from 30 participating medical centers that were 121 geographically distributed among the 9 USA Census divisions in 2017 as part of the SENTRY surveillance 122 platform (JMI Laboratories, North Liberty, IA, USA). The isolates evaluated in this study were collected 123 from patients with urinary tract infections according to defined protocols [20] . Only isolates determined 124 to be significant by local criteria as the reported probable cause of infection were included in the study. 125
Species identification was confirmed using standard biochemical tests and using a MALDI Biotyper 126 (Bruker Daltronics, Billerica, MA) according to the manufacturer's instructions. 127 6 provides query and analysis capability of the SENTRY Antimicrobial Surveillance Program database and it 149 was used for this study to generate national and regional resistance rates and analyze co-resistance for 150 the ESBL phenotypes as well as the susceptibility results for the blaCTX-M- 15 The results in Table 1 show the susceptibility results for different antimicrobial agents against the 1831  175 isolates of E. coli collected from UTI patients. Resistance to levofloxacin and ciprofloxacin were observed 176 in 24.3% and 25.8% of isolates, respectively. A TMP-SMX resistance phenotype was noted in 32.1% of 177 isolates. Using the oral breakpoints for cefuroxime, 36.8% of isolates were non-susceptible. In contrast, 178 the intravenous carbapenems including doripenem, ertapenem, imipenem and meropenem were all 179 highly active (≥99.4% susceptible) with little or no resistance being observed. Among other agents, 180 amikacin was also one of the most active agents with only 0.3% of the UTI isolates of E. coli being non-181 susceptible. Ampicillin-sulbactam was among one of the least active agents with 46% of the isolates 182 being non-susceptible. 183 the ESBL phenotypes were resistant to cefuroxime. High resistance rates were also observed for 197 ciprofloxacin and levofloxacin at 71.8% and 67.9%, respectively. There was also high resistance to TMP-198 SMX with 56.1% of the ESBL phenotypes being resistant. In contrast, the agents with the lowest 199 resistance rates were the intravenous carbapenems with none of the isolates being resistant to 
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Co-resistance among fluoroquinolone-resistant and TMP-SMX-resistant E. coli 208
The results in Table 2 show the resistance profiles of isolates that are either resistant to levofloxacin or 209 TMP-SMX. Among the levofloxacin-resistant E. coli co-resistance was observed for cefuroxime with 210 45.7% resistance and for TMP-SMX with 56.2% of the isolates being reported as resistant. Similarly, for 211 the TMP-SMX-resistant isolates of E. coli 31.3% were co-resistant to cefuroxime and 42.5% co-resistant 212 to levofloxacin. In contrast, little or no resistance was observed for the carbapenems against 213 levofloxacin and/or TMP-SMX-resistant isolates. 214
Susceptibility of blaCTX-M-15 genotypes of UTI isolates of E. coli 215
The blaCTX-M-15 genotypes were identified among 151 of the UTI isolates of E. coli collected in the USA 216 during 2017. The susceptibility results for various antimicrobial agents are shown in Table 3 . The isolates 217
were highly resistant to the fluoroquinolones with resistance rates of 81.5% and 83.4%, respectively, for 218 levofloxacin and ciprofloxacin. High resistance was also observed for TMP-SMX (69.5%) and cefuroxime 219 (100%). High resistance rates were also observed for many of the other agents tested with the exception 220 of the carbapenem where none of the isolates were resistant and amikacin where 1.3% of the isolates 221 were resistant. While oral antibiotics have been a mainstay of therapy for treating UTI's the results from this study show 231 that levofloxacin and/or TMP-SMX resistance rates are ≥ 24% among UTI isolates of E. coli collected in 232 the US during 2017. This increase in resistance suggests that considerable caution should be exercised 233 when choosing to use the fluoroquinolones as their widespread use has resulted in being implicated as a 234 "smoking gun" due to their role in promoting resistance [22] . This increase in fluoroquinolone-resistance 235 among UTI isolates of E. coli is now resulting in calls to combat their use as first choice agents [23] . In 236 this study fluoroquinolone resistance among UTI isolates of E. coli was also geographically distributed 237 across all nine Census regions. The mid-Atlantic region exhibited the highest prevalence of levofloxacin-238 resistant isolates of E. coli (38.1%) and is consistent with prevalence data from other studies [5, 14, 24] . 239
This study also showed the prevalence of ESBL phenotypes of E. coli from UTIs was 15.7% and many of 240 these isolates exhibited considerable co-resistance to many of the currently available oral agents. The 241 increase in prevalence of ESBLs is likely due to the widespread use of the cephalosporins [25] . Another 242 possible factor for the increased prevalence of ESBL phenotypes of E. coli is the global dissemination of 243 the ST131 clone that frequently carries blaCTX-M-15 [26] . In particular, E. coli 025b:H4/ST131 is now 244 prevalent in long term care facilities, exhibits co-resistance to the fluoroquinolones, aminoglycosides 245 and TMP-SMX, and now represents a considerable public health concern [11, 12]. The factors 246 responsible for the successful global dissemination of E. coli ST131 remain to be elucidated but may be 247 due to the type I fimbrial adhesins that may allow it to colonize the gastrointestinal tract more 248 efficiently [27] [28] [29] . 249
The ESBL phenotypes of E. coli reported in this study were geographically distributed across the nine 250
Census regions with the highest prevalence being among isolates collected in the mid-Atlantic region 251 and is similar to the high prevalence reported in previous studies [14] . To further evaluate the co-252 resistance among ESBL phenotypes, the resistance rates were determined for currently available oral 253 agents that included the fluoroquinolones and TMP-SMX and the high levels of co-resistance at ≥59% 254 have confirmed that high rates of co-resistance exist for contemporary isolates collected in 2017. 255 Furthermore, the increased resistance to TMP-SMX is equally concerning since this resistance is plasmid-256 mediated with genes that not only encode enzymes such as type II dihydrofolate reductase but also 257 additional genes that confer resistance to other antibiotic classes including the fluoroquinolones with This study not only assessed co-resistance among ESBL phenotypes but also among TMP-SMX and 260 fluoroquinolone-resistant isolates. Not surprisingly, the TMP-SMX-resistant isolates of E. coli exhibited 261 high co-resistance (≥ 30%) to the fluoroquinolones and cefuroxime. Also, the fluoroquinolone-resistant 262 isolates of E. coli exhibited high co-resistance (≥ 45%) to TMP-SMX and ceforuxime. The high co-263 resistance among the currently available oral agents suggests that, if you lose susceptibility to one, you 264 lose them all. 265
The increase in resistance to many of the currently available oral options makes the management of 266 that are prevalent among common Gram-negative UTI pathogens [31] . 280 
